Last reviewed · How we verify

NCT03242187: MansTaTME

Trans-anal Versus Laparoscopic TME for Mid and Low Rectal Cancer

Status unknown Phase 2, PHASE3 Last updated 8 August 2017
What this trial tests

Phase 2, PHASE3 trial testing Trans-anal total mesorectal excision(TaTME) in Rectal Cancer in 30 participants. Status unknown.

Timeline
25 May 2017
Primary endpoint
25 January 2019
30 December 2019

Quick facts

Lead sponsorMansoura University
PhasePhase 2, PHASE3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment30
Start date25 May 2017
Primary completion25 January 2019
Estimated completion30 December 2019
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Mansoura University

Who can join

18 and older, any sex, with Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to assess the surgical, oncological and functional outcome of either the laparoscopic or trans-anal TME in management of mid and low rectal cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

Other Mansoura University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03242187.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing